Phathom Pharmaceuticals (PHAT) News Today $8.78 -0.31 (-3.41%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Craig-Hallum Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)November 13, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business UpdatesNovember 11, 2024 | americanbankingnews.comPhathom Pharmaceuticals (PHAT) Receives a Buy from Stifel NicolausNovember 11, 2024 | markets.businessinsider.comPhathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9% - Here's What HappenedPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 8.9% - Time to Sell?November 8, 2024 | marketbeat.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 8, 2024 | finance.yahoo.comPhathom Pharmaceuticals Reports Significant Revenue GrowthNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price TargetNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look ForNovember 6, 2024 | finance.yahoo.comPhathom Pharmaceuticals (PHAT) Gets a Buy from Craig-HallumNovember 4, 2024 | markets.businessinsider.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comInvestors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%November 2, 2024 | finance.yahoo.comNeedham Sticks to Their Hold Rating for Lexicon Pharmaceuticals (LXRX)October 31, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayPhathom Pharmaceuticals (NASDAQ:PHAT) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640871)October 31, 2024 | marketbeat.comLow-Volume Bowel Prep Matches Standard for Inpatient ColonoscopyOctober 29, 2024 | msn.comPhathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024October 28, 2024 | globenewswire.comPhathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual MeetingOctober 27, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)October 25, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8% - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8% - Time to Buy?October 18, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 3.4% - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 3.4% - Time to Sell?October 14, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.5% - Should You Sell?Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5% - Should You Sell?October 7, 2024 | marketbeat.comMarshall Wace LLP Invests $1.16 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Marshall Wace LLP purchased a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 112,691 shares of the company's stock, valued at approximOctober 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 4.8% Higher Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 4.8%October 3, 2024 | marketbeat.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)September 25, 2024 | prnewswire.comOracle Investment Management Inc. Buys Shares of 225,000 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Oracle Investment Management Inc. purchased a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 225,000 shares of tSeptember 24, 2024 | marketbeat.comEnsign Peak Advisors Inc Sells 35,172 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Ensign Peak Advisors Inc trimmed its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 1.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,244,828 sharesSeptember 23, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High at $19.76Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High at $19.76September 19, 2024 | marketbeat.comBuy Rating Affirmed: Phathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Growth PotentialSeptember 14, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 1.6%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 1.6%September 13, 2024 | marketbeat.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday.September 13, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High at $18.67Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 1-Year High at $18.67September 11, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday.September 6, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High at $17.25Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High at $17.25September 5, 2024 | marketbeat.comPhathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Drives Buy RatingAugust 30, 2024 | markets.businessinsider.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 29, 2024 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Sets New 52-Week High at $15.84Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High at $15.84August 28, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 2.6%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 2.6%August 27, 2024 | marketbeat.comPhathom Pharmaceuticals’ V oquezna: A Rising Star in GERD Treatment MarketAugust 23, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded WarrantsAugust 19, 2024 | globenewswire.comPHAT Sep 2024 5.000 call (PHAT240920C00005000)August 17, 2024 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 3.5%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5%August 16, 2024 | marketbeat.comThis New Drug for GERD Works Better Than Proton Pump InhibitorsAugust 15, 2024 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Monday.August 12, 2024 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comMaintaining Hold on Phathom Pharmaceuticals Amidst Modest Voquezna Sales UptickAugust 9, 2024 | markets.businessinsider.comThe Goldman Sachs Group Raises Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $12.00The Goldman Sachs Group increased their price target on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a "neutral" rating in a research note on Friday.August 9, 2024 | marketbeat.comPHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Outperforms with Voquezna Driving Revenue Growth: Buy Rating ReaffirmedAugust 8, 2024 | markets.businessinsider.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.770.56▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼43▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC Pharmaceuticals News Nkarta News Karyopharm Therapeutics News BioXcel Therapeutics News Innoviva News Supernus Pharmaceuticals News Akero Therapeutics News NewAmsterdam Pharma News Scholar Rock News Recursion Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
